C9756

Colecalciferol

≥98% (HPLC)

• Sinónimos: (+)-Vitamina D₃, 7-deshidrocolesterol activado, Activado, 7-deshidrocolesterol, Calciol
• Fórmula empírica (notación de Hill): C₂₇H₄₄O
• Número CAS: 67-97-0
• Peso molecular: 384.64
• NACRES: NA.26
• PubChem Substance ID: 24893192
• eCl@ss: 34058003
• UNSPSC Code: 12352209
• EC Number: 200-673-2
• MDL number: MFCD00078131
• Beilstein/REAXYS Number: 2339331

Propiedades

• biological source: synthetic (organic)
• Quality Segment: 200
• assay: ≥98% (HPLC)
• form: powder
• technique(s): HPLC: suitable
• color: white to off-white
• mp: 83-86 °C (lit.)
• storage temp.: 2-8°C
• SMILES string: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]([C@]1(C)CCC/2)([H])C2=C\C=C(C[C@@H](O)CC3)/C3=C
• InChI: 1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
• InChI key: QYSXJUFSXHHAJI-YRZJJWOYSA-N
• Gene Information: human ... VDR(7421)

Descripción

General description

Cholecalciferol is sourced either through the diet or exposing skin to ultraviolet rays. Oral administration of vitamin D₃ is readily absorbed and is stored in adipose tissue.

Cholecalciferol acts as a hormone precursor since it requires two stages of metabolism: first to 25-hydroxycholecalciferol; then to 1α, 25-dihydroxycholecalciferol. One unit (U.S.P. or international) is defined as the activity of 0.025 μg of vitamin D3 contained in the USP vitamin D reference standard.

Application

• Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation.: This study delves into the significant roles of cholecalciferol in modulating the renal-bone axis, inflammatory responses, and iron metabolism in elderly patients with renal impairment. Through vitamin D supplementation, researchers observed pivotal changes that could guide future therapeutic strategies (Christodoulou M et al., 2024).


• Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study.: This clinical trial assesses the efficacy of cholecalciferol in improving the health outcomes of patients with multiple sclerosis. The use of cholecalciferol potentially enhances neurological function and reduces disease progression, illustrating its vital role in neurodegenerative disease management (Maghbooli Z et al., 2024).


• Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway.: This pivotal research links cholecalciferol to the reduction of COVID-19 severity through its regulatory effects on the NLRP3 inflammasome pathway. The findings underscore the potential of vitamin D as a modulatory agent in the immune response against viral infections (Khalil B et al., 2024).


• Effects of Vitamin D Supplementation on Central Hemodynamic Parameters and Autonomic Nervous System in Obese or Overweight Individuals.: This randomized controlled trial explores how cholecalciferol supplementation can affect cardiovascular and autonomic functions in obese or overweight patients, providing insights into its benefits beyond bone health and into cardiovascular regulation (Faria ACC et al., 2024).

Biochem/physiol Actions

Deficiency of vitamin D is often observed in chronic kidney disease.

La Vitamina D actúa a través de un receptor que forma parte de la superfamilia del factor de transcripción dependiente del ligando. Modula la proliferación y diferenciación de las células normales y cancerosas. Tiene efectos contrarios a la proliferación y desarrollo de metástasis en células de cáncer de mama, colon y próstata. Receptores activados de vitamina D en el intestino y los huesos mantienen la absorción de calcio y la homeostasis.

La vitamina D actúa a través de un receptor que modula la proliferación y la diferenciación tanto de las células sanas como de las cancerosas.

Preparation Note

Cholecalciferol C9756 is packaged under argon gas. If it is stored unopened at 2-8°C and protected from light, this product should be stable for a minimum of three years. Unused portions should be stored under nitrogen or argon gas. Deterioration is negligible after storage of one year in amber-evaculated ampules at refrigerator temperatures. It is oxidized and inactivated by moist air within a few days.

Información de seguridad

• pictograms: GHS06,GHS08
• signalword: Danger
• hcodes: H300 + H310 + H330,H372
• pcodes: P260 - P262 - P280 - P302 + P352 + P310 - P304 + P340 + P310 - P314
• Hazard Classifications: Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - STOT RE 1 Oral
• Clase de almacenamiento: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges